In the past decade, several biologics that are primarily aimed at inhibiting TNF-α, blocking IL-12, and IL-23, or interfering with Th17 cell development have been approved for the treatment of psoriasis (Mahil et al., 2016). Here, TNF is linked to psoriasis.